Trump Nominates Chris Klomp as HHS Second-in-Command
Trump nominates Chris Klomp as HHS second – President Donald Trump has announced his intention to nominate Chris Klomp as the deputy secretary of the U.S. Department of Health and Human Services (HHS), placing him in a critical leadership role within the agency. Klomp, currently serving as Medicare director and a former healthcare executive, will assist HHS Secretary Robert F. Kennedy Jr. in overseeing the department’s operations and shaping its regulatory policies. The nomination marks a strategic move to reinforce Trump’s vision for healthcare reform, particularly in the context of ongoing initiatives like the TrumpRx program, which aims to reduce drug costs and streamline health services.
The decision to appoint Klomp follows a period of significant turnover in HHS leadership. The agency had been without a deputy secretary since the departure of Jim O’Neill in February 2026, part of a broader restructuring effort to realign priorities under the Trump administration. This shift has seen a focus on cost-cutting measures and modernizing healthcare delivery systems. Klomp’s selection signals a continued commitment to these goals, with his experience in managing large-scale healthcare programs expected to play a key role in the department’s future direction.
Chris Klomp’s Background and Expertise
Before his current role as Medicare director, Chris Klomp built a career in healthcare management and policy. He served as a senior executive at a major pharmaceutical company, where he oversaw operations and strategic partnerships. Klomp’s tenure in the private sector equipped him with the skills to navigate complex regulatory frameworks and drive efficiency in public health programs. His ability to translate administrative acumen into actionable policies has been a key asset in his recent position, where he has been instrumental in implementing the most-favored nations (M-FN) plan—a cornerstone of Trump’s pharmaceutical strategy.
“Chris Klomp has been unbelievable, a real star,” Trump remarked during a White House event in April 2026, while celebrating a landmark agreement with Regeneron. “You don’t know his name as much as some of the others, but he’s a real star of the group.”
The president’s praise underscores Klomp’s growing influence within the administration, despite his relative anonymity in the public eye. His role in advancing the M-FN plan, which seeks to lower prescription drug prices by benchmarking them against international rates, has been a highlight of his leadership at the Centers for Medicare & Medicaid Services (CMS).
Leadership in Key Health Initiatives
As Medicare director since April 2025, Klomp has been at the forefront of Trump’s efforts to overhaul the healthcare system. His work on pharmaceutical negotiations with companies like Regeneron has demonstrated a deep understanding of both regulatory and business dynamics. Klomp’s approach has emphasized cost containment, with a particular focus on ensuring that Medicare beneficiaries receive affordable medications. This aligns with the broader Trump administration’s goal of making healthcare more accessible and less expensive for American families.
Klomp’s leadership also extends to the selection of key officials within the HHS. He has played a central role in identifying and vetting candidates for the FDA commissioner post, following the resignation of Dr. Marty Makary in May 2026. His involvement in the recruitment process for the CDC director and surgeon general further highlights his importance in shaping the department’s top-tier appointments. These positions are critical to the implementation of Trump’s healthcare agenda, and Klomp’s guidance is expected to ensure a cohesive strategy across all HHS branches.
Trump’s decision to nominate Klomp reflects a blend of experience and loyalty. While the president has often highlighted figures with national recognition, Klomp’s close alignment with Kennedy Jr. and his track record in managing intricate healthcare programs have made him a valuable asset. His appointment also signals a move to consolidate decision-making power, with the deputy secretary role serving as a bridge between the HHS Secretary and the department’s operational leaders. This structure is designed to expedite policy implementation and maintain consistency in Trump’s healthcare vision.
Additional details about Klomp’s role in the HHS reveal a focus on both administrative efficiency and legislative advocacy. He has been actively involved in drafting proposals for healthcare reforms, with an emphasis on private-sector partnerships and reducing federal oversight. Klomp’s expertise in managing large organizations has been particularly useful in streamlining processes within the HHS, ensuring that resources are allocated effectively to support Trump’s key priorities. His ability to work across different healthcare sectors—public and private—has made him a strategic choice for this high-profile position.
The nomination of Chris Klomp as HHS deputy secretary has sparked discussions about the future of healthcare policy under the Trump administration. With his experience in cost reduction and his close ties to Kennedy Jr., Klomp is positioned to influence major decisions on drug pricing, insurance regulations, and public health programs. Analysts note that his background in the private sector may bring a fresh perspective to the HHS, reinforcing the administration’s push to integrate market-driven solutions into federal healthcare initiatives. As the nation continues to navigate challenges in the healthcare landscape, Klomp’s leadership is expected to play a pivotal role in shaping the next phase of policy development.
